- Home
- ENVX vs SLNO Comparison
ENVX vs SLNO Comparison
Compare ENVX & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVX
- SLNO
- Stock Information
- Founded
- ENVX 2006
- SLNO 1999
- Country
- ENVX United States
- SLNO United States
- Employees
- ENVX N/A
- SLNO N/A
- Industry
- ENVX Industrial Machinery/Components
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ENVX Miscellaneous
- SLNO Health Care
- Exchange
- ENVX Nasdaq
- SLNO Nasdaq
- Market Cap
- ENVX 2.1B
- SLNO 2.3B
- IPO Year
- ENVX N/A
- SLNO 2014
- Fundamental
- Price
- ENVX $6.16
- SLNO $69.98
- Analyst Decision
- ENVX Strong Buy
- SLNO Strong Buy
- Analyst Count
- ENVX 12
- SLNO 8
- Target Price
- ENVX $20.17
- SLNO $95.75
- AVG Volume (30 Days)
- ENVX 6.0M
- SLNO 2.6M
- Earning Date
- ENVX 04-30-2025
- SLNO 05-08-2025
- Dividend Yield
- ENVX N/A
- SLNO N/A
- EPS Growth
- ENVX N/A
- SLNO N/A
- EPS
- ENVX N/A
- SLNO N/A
- Revenue
- ENVX $23,074,000.00
- SLNO N/A
- Revenue This Year
- ENVX $53.27
- SLNO N/A
- Revenue Next Year
- ENVX $313.37
- SLNO N/A
- P/E Ratio
- ENVX N/A
- SLNO N/A
- Revenue Growth
- ENVX 201.86
- SLNO N/A
- 52 Week Low
- ENVX $5.27
- SLNO $36.61
- 52 Week High
- ENVX $18.68
- SLNO $74.00
- Technical
- Relative Strength Index (RSI)
- ENVX 39.70
- SLNO 62.10
- Support Level
- ENVX $5.69
- SLNO $57.01
- Resistance Level
- ENVX $6.40
- SLNO $71.00
- Average True Range (ATR)
- ENVX 0.69
- SLNO 5.29
- MACD
- ENVX 0.01
- SLNO -0.08
- Stochastic Oscillator
- ENVX 35.46
- SLNO 76.34
About ENVX Enovix Corporation
Enovix Corp is engaged in the business of advanced silicon-anode lithium-ion battery development and production. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable the widespread utilization of renewable energy.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.